Loading
Life sciences · Journal article
Molecular Cancer Therapeutics · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Gastroesophageal adenocarcinoma (GEAC) is a significant global cancer burden. Our previous studies demonstrated that YAP/TEAD are highly expressed in GEAC, and play a critical role in tumor progression, therapy resistance, and metastasis. Thus, targeting YAP/TEAD signaling presents a promising therapeutic strategy. Here, we demonstrate that VT00278, a novel compound derived from YAP/TEAD inhibitor CA3, strongly downregulated YAP/TEAD transcriptional activity and potently suppressed tumor-promoting phenotypes including proliferation, invasion and tumor sphere formation. VT00278 induced apoptosis and inhibited tumor growth in vivo especially in radiation-resistant FLO-1 XTR esophageal cancer cells. Mechanistically, in addition to impairing YAP/TEAD signal, VT00278 or YAP depletion repressed RNA polymerase II (RNAPII) transcriptional regulators, reduced RNAPII S2 phosphorylation and decreased anti-apoptotic MCL-1 expression. More interestingly, VT00278 strongly inhibited DNA damage repair, activated cytosolic DNA sensing pathway, and upregulated innate immune genes (e.g., IFNβ). Meanwhile, the upregulation of PD-L1 in VT00278-treated tumor cells possibly contributes to a suppressive immune microenvironment. In a KP-luc2 syngeneic gastric cancer mouse model, combining VT00278 with anti-PD-1 therapy strongly inhibited tumor growth, increased CD3+ and CD8+ T cell infiltration, and induced the production of IFNγ from CD3 and CD8 cells. These findings support that targeting YAP/TEAD with VT00278 as a promising novel therapeutic strategy for GEAC treatment, either alone or in combination with immunotherapy.